Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

Ductal Carcinoma Clinical Trial

Official title:
A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel + Anthracycline x 4 Cycles Followed by Docetaxel Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed ≥ 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere®- Based Chemotherapy

Status Terminated

Clinical Trial Summary

Primary: To determine the pathological remission following the chemotherapy combination docetaxel and doxorubicin in large breast cancer

Secondary:

- Clinical response rate

- To investigate the safety of docetaxel doxorubicin combination in the treatment for neoadjuvant chemotherapy of breast cancer

- Type of surgery (radical/conservative)

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00461344
Study type	Interventional
Source	Sanofi
Contact
Status	Terminated
Phase	Phase 2
Start date	July 2004
Completion date	August 2007

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02779855` - Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT01208974` - Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction	N/A
Completed	`NCT01796041` - Intraoperative Imaging of Breast Cancer With Indocyanine Green	Early Phase 1